Acromegaly Major Markets: Drugs, Epidemiology, Trends, Opportunities, Forecast (2024-2034) Featuring Novartis, Pfizer, Crinetics Pharmaceuticals, Camurus [Yahoo! Finance]
Crinetics Pharmaceuticals, Inc. (CRNX)
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
The 7 major acromegaly markets are expected to exhibit a CAGR of 8.1% during 2023-2034. Market Trends The increasing prevalence of changes in certain genes within the pituitary cells that can lead to the development of adenomas is primarily driving the acromegaly market. In addition to this, the inflating utilization of efficacious medications like somatostatin analogs, growth hormone receptor antagonists, and dopamine agonists to regulate hormone levels and manage symptoms effectively is also creating a positive outlook for the market. Moreover, the widespread adoption of surgical interventions, such as transsphenoidal surgery and radiation therapy, which aim to remove or shrink the pituitary tumor responsible for the excess GH production in individuals suffering from the illness, is further bolstering the market growth. Apart from this, the rising usage of physical and occupational therapies, since they assist in improving mobility, enhancing muscle strength, and addressi
Show less
Read more
Impact Snapshot
Event Time:
CRNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRNX alerts
High impacting Crinetics Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRNX
News
- EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner [Yahoo! Finance]Yahoo! Finance
- EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award WinnerGlobeNewswire
- Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $80.00 price target on the stock.MarketBeat
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $55.00 to $74.00. They now have an "outperform" rating on the stock.MarketBeat
CRNX
Earnings
- 5/9/24 - Miss
CRNX
Sec Filings
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- CRNX's page on the SEC website